For example, decitabine-primed tandem CD19/CD20 CAR-T cells treatment in relapsed/refractory B-cell NHL (r/r B-cell NHL) (NCT04697940), sequential low-dose decitabine with PD-1/CD28, CD19 CAR-T in relapsed/refractory B-cell lymphoma (r/r B-cell lymphoma) (NCT04850560). Here, CD19 is linked to B-cell non-Hodgkin lymphoma.